Incus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.51 M
as on 16-11-2024
- Paid Up Capital ₹ 0.51 M
as on 16-11-2024
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.76 M
as on 16-11-2024
- Revenue 104.50%
(FY 2023)
- Profit 46302.60%
(FY 2023)
- Ebitda 1851.58%
(FY 2023)
- Net Worth 48.17%
(FY 2023)
- Total Assets 121.56%
(FY 2023)
About Incus Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.51 M and a paid-up capital of Rs 0.51 M.
The company currently has active open charges totaling ₹3.76 M.
Thulaseedharan Kumar, Narayanan Das, Plammoottil Abhilash, and One other member serve as directors at the Company.
- CIN/LLPIN
U51397KL2009PTC024907
- Company No.
024907
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Oct 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Incus Pharmaceuticals Private Limited offer?
Incus Pharmaceuticals Private Limited offers a wide range of products and services, including Health Conditions, Cold & Cough.
Who are the key members and board of directors at Incus Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narayanan Das  | Managing Director | 21-Oct-2009 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Babu Philip | Whole-Time Director | 21-Oct-2009 | Current |
| Thulaseedharan Kumar | Whole-Time Director | 21-Oct-2009 | Current |
| Plammoottil Abhilash | Director | 08-Dec-2022 | Current |
Financial Performance of Incus Pharmaceuticals.
Incus Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 104.5% increase. The company also saw a substantial improvement in profitability, with a 46302.6% increase in profit. The company's net worth Soared by an impressive increase of 48.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Incus Pharmaceuticals?
In 2023, Incus Pharmaceuticals had a promoter holding of 93.00% and a public holding of 7.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 08 May 2024 | ₹1.03 M | Open |
Hdfc Bank Limited Creation Date: 27 Jun 2022 | ₹0.73 M | Open |
State Bank Of India Creation Date: 17 Oct 2019 | ₹2.00 M | Open |
How Many Employees Work at Incus Pharmaceuticals?
Unlock and access historical data on people associated with Incus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Incus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Incus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
